CA2233278A1 - Stimulation de reponses immunes cellulaires par une imunisation genique ciblee utilisant un agent particulaire - Google Patents
Stimulation de reponses immunes cellulaires par une imunisation genique ciblee utilisant un agent particulaire Download PDFInfo
- Publication number
- CA2233278A1 CA2233278A1 CA002233278A CA2233278A CA2233278A1 CA 2233278 A1 CA2233278 A1 CA 2233278A1 CA 002233278 A CA002233278 A CA 002233278A CA 2233278 A CA2233278 A CA 2233278A CA 2233278 A1 CA2233278 A1 CA 2233278A1
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- tumor rejection
- host
- particulate
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000002068 genetic effect Effects 0.000 title claims abstract description 40
- 230000003053 immunization Effects 0.000 title claims abstract description 16
- 238000002649 immunization Methods 0.000 title claims abstract description 16
- 230000000638 stimulation Effects 0.000 title description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract description 173
- 108091007433 antigens Proteins 0.000 claims abstract description 165
- 102000036639 antigens Human genes 0.000 claims abstract description 160
- 239000000427 antigen Substances 0.000 claims abstract description 159
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 101
- 239000002157 polynucleotide Substances 0.000 claims abstract description 101
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 101
- 238000000034 method Methods 0.000 claims abstract description 76
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 74
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 65
- 230000000890 antigenic effect Effects 0.000 claims abstract description 47
- 239000012634 fragment Substances 0.000 claims abstract description 43
- 241000282414 Homo sapiens Species 0.000 claims abstract description 38
- 210000000805 cytoplasm Anatomy 0.000 claims abstract description 15
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 13
- 238000002347 injection Methods 0.000 claims description 94
- 239000007924 injection Substances 0.000 claims description 94
- 206010028980 Neoplasm Diseases 0.000 claims description 90
- 230000037361 pathway Effects 0.000 claims description 57
- 108020004414 DNA Proteins 0.000 claims description 56
- 102000043129 MHC class I family Human genes 0.000 claims description 40
- 108091054437 MHC class I family Proteins 0.000 claims description 40
- 230000003612 virological effect Effects 0.000 claims description 29
- 210000003563 lymphoid tissue Anatomy 0.000 claims description 26
- 238000000338 in vitro Methods 0.000 claims description 24
- 238000001727 in vivo Methods 0.000 claims description 19
- 239000012528 membrane Substances 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 14
- 230000000069 prophylactic effect Effects 0.000 claims description 12
- 238000010254 subcutaneous injection Methods 0.000 claims description 9
- 239000007929 subcutaneous injection Substances 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 7
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 108010010995 MART-1 Antigen Proteins 0.000 claims description 6
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 6
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 6
- 101150029707 ERBB2 gene Proteins 0.000 claims description 5
- 208000002672 hepatitis B Diseases 0.000 claims description 5
- 238000012737 microarray-based gene expression Methods 0.000 claims description 5
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 5
- 108090000978 Interleukin-4 Proteins 0.000 claims description 4
- 108010065805 Interleukin-12 Proteins 0.000 claims description 3
- 102000011931 Nucleoproteins Human genes 0.000 claims 4
- 108010061100 Nucleoproteins Proteins 0.000 claims 4
- 241000712461 unidentified influenza virus Species 0.000 claims 4
- 108020004511 Recombinant DNA Proteins 0.000 claims 2
- 230000030741 antigen processing and presentation Effects 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 210000005170 neoplastic cell Anatomy 0.000 abstract description 17
- 230000036039 immunity Effects 0.000 abstract description 11
- 230000006378 damage Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 51
- 108010058846 Ovalbumin Proteins 0.000 description 45
- 229940092253 ovalbumin Drugs 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 32
- 108090000765 processed proteins & peptides Proteins 0.000 description 31
- 210000001519 tissue Anatomy 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 26
- 230000014509 gene expression Effects 0.000 description 25
- 239000011324 bead Substances 0.000 description 18
- 230000006698 induction Effects 0.000 description 15
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 14
- 239000010931 gold Substances 0.000 description 14
- 229910052737 gold Inorganic materials 0.000 description 14
- 210000004443 dendritic cell Anatomy 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 12
- 210000000170 cell membrane Anatomy 0.000 description 11
- 230000002500 effect on skin Effects 0.000 description 11
- 230000008685 targeting Effects 0.000 description 11
- 241001529936 Murinae Species 0.000 description 10
- 238000010253 intravenous injection Methods 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 230000000242 pagocytic effect Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 210000000172 cytosol Anatomy 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 201000001441 melanoma Diseases 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 230000032258 transport Effects 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 210000004408 hybridoma Anatomy 0.000 description 7
- 101150066555 lacZ gene Proteins 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 230000009261 transgenic effect Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 231100000518 lethal Toxicity 0.000 description 6
- 230000001665 lethal effect Effects 0.000 description 6
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 208000001382 Experimental Melanoma Diseases 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 230000001926 lymphatic effect Effects 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 210000000712 G cell Anatomy 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108091061960 Naked DNA Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241000282320 Panthera leo Species 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102100029450 M1-specific T cell receptor alpha chain Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 210000003595 dermal dendritic cell Anatomy 0.000 description 2
- 210000003426 epidermal langerhans cell Anatomy 0.000 description 2
- -1 gplOO Proteins 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- GSSMIHQEWAQUPM-AOLPDKKJSA-N ovalbumin peptide Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CN=CN1 GSSMIHQEWAQUPM-AOLPDKKJSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 101150110188 30 gene Proteins 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 101150020229 Apcs gene Proteins 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101100452236 Caenorhabditis elegans inf-1 gene Proteins 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 101150023426 Ccin gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 101100390736 Danio rerio fign gene Proteins 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101100207408 Homo sapiens TRA gene Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 101100390738 Mus musculus Fign gene Proteins 0.000 description 1
- 101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000312117 Phago Species 0.000 description 1
- 235000014548 Rubus moluccanus Nutrition 0.000 description 1
- 101150115433 SLC26A5 gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710137302 Surface antigen S Proteins 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229940022007 naked DNA vaccine Drugs 0.000 description 1
- 238000011815 naïve C57Bl6 mouse Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- RJSZPKZQGIKVAU-UXBJKDEOSA-N peptide f Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C(C)C)C(C)C)C1=CC=CC=C1 RJSZPKZQGIKVAU-UXBJKDEOSA-N 0.000 description 1
- NTGBUUXKGAZMSE-UHFFFAOYSA-N phenyl n-[4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl]carbamate Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(NC(=O)OC=3C=CC=CC=3)=CC=2)CC1 NTGBUUXKGAZMSE-UHFFFAOYSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Pregnancy & Childbirth (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
L'invention concerne différentes méthodes d'immunisation génétique permettant de conférer une immunité à un mammifère hôte vis-à-vis d'un antigène spécifique, en particulier un hôte humain. L'invention se base sur la faculté de diriger des polynucléotides particulaires, capables d'exprimer une protéine ou un fragment de protéine antigénique, sur le cytoplasme des cellules cibles hôtes, telles que les cellules présentant l'antigène. Un apport direct de ces polynucléotides particulaires dans le cytoplasme des cellules présentant l'antigène va stimuler la production de lymphocytes cytotoxiques spécifiques de l'antigène, ce qui va favoriser la destruction de cellules malades, telles que les cellules néoplasiques et les cellules infectées par un virus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53555695A | 1995-09-28 | 1995-09-28 | |
US08/535,556 | 1995-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2233278A1 true CA2233278A1 (fr) | 1997-04-03 |
Family
ID=24134735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002233278A Abandoned CA2233278A1 (fr) | 1995-09-28 | 1996-09-27 | Stimulation de reponses immunes cellulaires par une imunisation genique ciblee utilisant un agent particulaire |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0863704A4 (fr) |
JP (1) | JPH11512724A (fr) |
KR (1) | KR19990063672A (fr) |
CN (1) | CN1201369A (fr) |
AU (1) | AU716497B2 (fr) |
BG (1) | BG102355A (fr) |
CA (1) | CA2233278A1 (fr) |
CZ (1) | CZ92998A3 (fr) |
HU (1) | HUP9802651A3 (fr) |
NO (1) | NO981386L (fr) |
NZ (1) | NZ319891A (fr) |
PL (1) | PL325953A1 (fr) |
SK (1) | SK40198A3 (fr) |
TR (1) | TR199800573T2 (fr) |
WO (1) | WO1997011605A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3210997A (en) * | 1996-05-24 | 1997-12-09 | University Of Maryland At Baltimore | Dna vaccines for eliciting a mucosal immune response |
TW570803B (en) * | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
US6287569B1 (en) * | 1997-04-10 | 2001-09-11 | The Regents Of The University Of California | Vaccines with enhanced intracellular processing |
WO1999041368A2 (fr) * | 1998-02-11 | 1999-08-19 | Maxygen, Inc. | Optimisation des proprietes immunomodulatrices des vaccins genetiques |
JP2003523721A (ja) | 1998-12-31 | 2003-08-12 | カイロン コーポレイション | 抗原性hivc型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用 |
WO2000063385A2 (fr) * | 1999-04-21 | 2000-10-26 | Powderject Vaccines, Inc. | Immunisation de l'acide nucleique |
ATE411044T1 (de) * | 2001-03-30 | 2008-10-15 | Ghc Res Dev Corp | Monozyte-spezifisches teilchenförmiges verabreichungsvehikel |
CA2634992C (fr) | 2001-07-05 | 2012-10-16 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations |
US11529414B2 (en) | 2020-06-23 | 2022-12-20 | Orbis Health Solutions, Llc | Viral vaccines for in vivo expression of a nucleic acid encoding an immunogenic peptide and methods of using the same |
-
1996
- 1996-09-27 PL PL96325953A patent/PL325953A1/xx unknown
- 1996-09-27 KR KR1019980702134A patent/KR19990063672A/ko not_active Application Discontinuation
- 1996-09-27 CA CA002233278A patent/CA2233278A1/fr not_active Abandoned
- 1996-09-27 SK SK401-98A patent/SK40198A3/sk unknown
- 1996-09-27 TR TR1998/00573T patent/TR199800573T2/xx unknown
- 1996-09-27 HU HU9802651A patent/HUP9802651A3/hu unknown
- 1996-09-27 EP EP96933987A patent/EP0863704A4/fr not_active Withdrawn
- 1996-09-27 JP JP9513762A patent/JPH11512724A/ja active Pending
- 1996-09-27 CN CN96198106A patent/CN1201369A/zh active Pending
- 1996-09-27 NZ NZ319891A patent/NZ319891A/xx unknown
- 1996-09-27 CZ CZ98929A patent/CZ92998A3/cs unknown
- 1996-09-27 AU AU72515/96A patent/AU716497B2/en not_active Ceased
- 1996-09-27 WO PCT/US1996/015728 patent/WO1997011605A1/fr not_active Application Discontinuation
-
1998
- 1998-03-26 NO NO981386A patent/NO981386L/no unknown
- 1998-03-26 BG BG102355A patent/BG102355A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP0863704A1 (fr) | 1998-09-16 |
HUP9802651A2 (hu) | 1999-02-01 |
SK40198A3 (en) | 1998-11-04 |
EP0863704A4 (fr) | 2003-09-10 |
WO1997011605A1 (fr) | 1997-04-03 |
CZ92998A3 (cs) | 1998-09-16 |
NO981386D0 (no) | 1998-03-26 |
HUP9802651A3 (en) | 2001-08-28 |
KR19990063672A (ko) | 1999-07-26 |
NO981386L (no) | 1998-05-28 |
PL325953A1 (en) | 1998-08-17 |
TR199800573T2 (xx) | 1998-07-21 |
BG102355A (en) | 1999-04-30 |
NZ319891A (en) | 1999-01-28 |
AU716497B2 (en) | 2000-02-24 |
AU7251596A (en) | 1997-04-17 |
CN1201369A (zh) | 1998-12-09 |
JPH11512724A (ja) | 1999-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yoshikawa et al. | Nanoparticles built by self-assembly of amphiphilic γ-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells | |
Chikh et al. | Liposomal delivery of CTL epitopes to dendritic cells | |
EP1083232B1 (fr) | Transfert de mARN á l'aide de composés polycationiques | |
AU2007269245B2 (en) | Dendritic cells generated using GM-CSF and interferon alpha and loaded with heat-treated and killed cancer cells | |
US9814682B2 (en) | Vaccination with immuno-isolated cells producing an immunomodulator | |
KR100850473B1 (ko) | 면역원성이 불량한 항원의 면역원성을 향상시키는 약제조성물 | |
US7247310B1 (en) | Tumor vaccines | |
Kjaergaard et al. | Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine | |
EP1660040A1 (fr) | Ciblage in vivo de cellules dendritiques | |
Cayeux et al. | Direct and indirect T cell priming by dendritic cell vaccines | |
KR20070068398A (ko) | 재조합 마이코박테리움의 조합물 및 백신과 같은 생물학적활성제 | |
CA2233278A1 (fr) | Stimulation de reponses immunes cellulaires par une imunisation genique ciblee utilisant un agent particulaire | |
US6491925B2 (en) | Compositions and methods for cancer prophylaxis and/or treatment | |
US8053421B2 (en) | DNA vaccines against tumor growth and methods of use thereof | |
WO1990011085A1 (fr) | Immunogene multivalent de grande taille | |
US7176186B1 (en) | Stimulation of cell-mediated immune responses by targeted particulate genetic immunization | |
US20040146486A1 (en) | Hybrid vector system for use as a vaccine | |
Wu et al. | Native anti-tumor responses elicited by immunization with a low dose of unmodified live tumor cells | |
MXPA98002405A (en) | Stimulation of medium immune response in objective cells through genetic immunization in particu | |
EP1222252A1 (fr) | Nouveaux lymphocytes, procede de preparation de ces lymphocytes et utilisation de ces derniers dans un traitement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |